Sponsors, CROs and academic research teams choosing an eCOA platform for a regulated clinical trial.
Scope Electronic clinical outcome assessment (eCOA) platforms that capture patient-reported (ePRO), clinician-reported, observer-reported and performance outcomes in regulated clinical trials, as a sponsor, CRO or academic research team would shortlist them.
These notes describe the products in the eCOA guide.
Kayentis
Best for
Phase II-III sponsors that want a specialist eCOA vendor with site and patient helpdesk support
What to consider
Kayentis is an eCOA specialist with 280+ trials in 85 countries and 120 languages, and its Clin'form app runs on BYOD, provisioned devices, web and interview mode. It does not publish build timelines, approval counts or prices.
Large sponsors and CROs that already run Rave EDC and want eCOA in the same platform
What to consider
Medidata eCOA lists 2,500+ COAs, 200+ languages and dialects and 1,600+ studies, and data flows straight into Rave EDC. Study builders can configure it in Medidata Designer, with an average study start of 8 weeks. Prices are not published.
Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.
Expand a feature definition or support note for context and its original source.
Kayentis vs Medidata eCOA (eCOA): category feature evidence and sources. Products are not ranked.
Category feature
Kayentis
Medidata eCOA
Validated instrument library and licensingFeature definitions
Supported
A library of outcome-assessment instruments is documented.
Extended support
A validated or instrument-author-approved library plus managed instrument licensing are documented.
Kayentis
Extended support
Questionnaire library and translation tools built with linguistic validation agencies; licensing and validation handled with language-service partners.
The questionnaire library is paired with licensing and validation handled by language-service partners.
Medidata eCOA
Extended support
2,500+ COAs and a global instrument library for reusing builds and translations; Medidata also offers a validated instrument license management service.
Medidata says its AI functionality supports 80% of 2025 FDA novel drug approvals (company-wide platform claim, not eCOA alone); position statements on Part 11, Annex 11 and ICH E6 are published.
Vendor-led setup is described; timelines and self-service tooling are not published.
Medidata eCOA
Extended support
Medidata Designer lets study builders configure questionnaires with drag-and-drop templates; average study start 8 weeks versus a 12-week industry standard.
Sales contact alone does not establish a published pricing model, prices or contract terms.
Unknown does not mean unavailable. The public evidence does not establish support under this category’s definition.
Medidata eCOA
Supported
No prices published; Medidata's public Patient Cloud service descriptions set out contract terms, such as devices provisioned on a rental basis, caps on fee adjustments and early-termination fees.